Phaseline

Companies › T.O.A.D. Oncology

T.O.A.D. Oncology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TD001
anti-PSMA antibody-drug conjugate
FOLH1Phase 1Metastatic Castration-Resistant Prostatic CancerMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07258407TD001Phase 1Metastatic Castration-Resistant Prostatic CancerOncologyMar 2028

Targets

FOLH1 (1)

Companies with the same targets

Novartis Johnson & Johnson (Janssen) Telix Pharmaceuticals (Innovations) Clarity Pharmaceuticals Convergent Therapeutics Fusion Pharmaceuticals Five Eleven Pharma VitsGen Therapeutics Endocyte AstraZeneca

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.